AI assistant
GlaxoSmithKline PLC — Director's Dealing 2019
Jan 15, 2019
5262_dirs_2019-01-15_68b8ec62-7ff9-4488-b0c4-13459d9812c8.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 1864N
GlaxoSmithKline PLC
15 January 2019
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E N Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.2875 | 1535.597 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-01-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.2875 | 42.320 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-01-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S P Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.2875 | 1050.550 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the
transaction
2019-01-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.2875 | 0.012 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-01-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 January 2019.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $39.4400 | 75.536 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-01-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.2875 | 309.578 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-01-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 January 2019
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $39.4400 | 18.799 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-01-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
Acquisition of ADSs following the re-investment of dividends paid to shareholders on 10 January 2019
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| $39.4400 | 424.074 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-01-11
f)
Place of the transaction
New York Stock Exchange (XNYS)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.2875 | 1945.478 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-01-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Simard
b)
Position/status
President, Pharma Supply Chain
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.2875 | 363.181 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-01-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, Human Resources
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.2875 | 357.061 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-01-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.2875 | 210.297 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-01-11
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs K Thomson
b)
Position/status
PCA of Mr P C Thomson (President, Global Affairs)
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019.
c)
Price(s) and volume(s)
| Price(s) | Volume(s) |
| £15.2875 | 127.445 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2019-01-11
f)
Place of the transaction
London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHDELFFKFFFBBX